Loading…
Influx Healthtech (INFLUX)₹253.00−1.94%Pharmaceuticals
In the Mar 2026 quarter (standalone), Influx Healthtech reported sales of ₹79.76 Cr, up 40.3% from Mar 2025, and net profit of ₹11.02 Cr, up 37.4% year on year. For the year to Mar 2026, sales were ₹147 Cr and net profit ₹21.04 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales | 47.88 | 56.85 | 66.90 | 79.76 |
| Expenses | 39.07 | 45.07 | 52.11 | 65.16 |
| Operating Profit | 9.02 | 11.02 | 15.05 | 15.04 |
| OPM % | 18.9% | 19.9% | 21.9% | 18.9% |
| Other Income | 0.00 | 0.00 | 0.00 | 1.01 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.99 | 1.99 | 1.99 | 1.99 |
| Profit before tax | 8.01 | 10.01 | 13.01 | 14.01 |
| Tax % | 27.0% | 24.0% | 23.0% | 25.0% |
| Net Profit | 6.01 | 8.02 | 10.02 | 11.02 |
| EPS (Rs) | 3.11 | 4.22 | 4.33 | 4.57 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales | 58.86 | 75.88 | 99.78 | 105 | 147 |
| Expenses | 53.09 | 65.17 | 83.17 | 84.13 | 117 |
| Operating Profit | 6.02 | 11.03 | 17.04 | 21.05 | 30.09 |
| OPM % | 10.9% | 14.0% | 16.9% | 19.9% | 19.9% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.99 | 1.99 | 2.99 | 3.99 |
| Profit before tax | 6.01 | 10.01 | 15.02 | 18.02 | 27.02 |
| Tax % | 26.0% | 26.0% | 25.0% | 25.0% | 25.0% |
| Net Profit | 4.01 | 7.02 | 11.03 | 13.03 | 21.04 |
| EPS (Rs) | 1,804.07 | 2,887.98 | 4,462.85 | 7.39 | 8.89 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0.03 | 0.04 | 0.04 | 0.04 | 18.04 | 23.06 |
| Reserves | 0.00 | 4.01 | 12.01 | 23.02 | 18.02 | 78.11 |
| Borrowings | 0.00 | 0.99 | 0.99 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 12.02 | 16.05 | 18.09 | 34.13 | 23.11 |
| Total Liabilities | 0.00 | 18.03 | 28.06 | 41.12 | 70.19 | 124 |
| Fixed Assets | 0.00 | 2.99 | 5.99 | 14.02 | 18.99 | 28.03 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.99 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.01 |
| Other Assets | 0.00 | 15.04 | 22.07 | 27.10 | 52.20 | 90.25 |
| Inventories | 0.00 | 1.74 | 1.95 | 5.44 | 13.16 | 15.86 |
| Trade receivables | 0.00 | 10.27 | 13.78 | 15.85 | 32.31 | 33.65 |
| Cash & equivalents | 0.03 | 1.48 | 3.56 | 3.62 | 1.92 | 25.19 |
| Total Assets | 0.00 | 18.03 | 28.06 | 41.12 | 70.19 | 124 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from operating activity | 4.01 | 7.01 | 9.02 | 7.02 | 4.01 |
| Cash from investing activity | −3.01 | −5.01 | −8.01 | −9.02 | −25.03 |
| Cash from financing activity | 1.01 | 0.00 | −1.01 | 0.00 | 45.06 |
| Net cash flow | 1.01 | 2.01 | 0.00 | −2.01 | 23.02 |
| Capex | 2.85 | 4.87 | 8.34 | 8.19 | 24.47 |
| Free cash flow | 0.99 | 1.99 | 0.99 | −0.99 | −20.97 |
| CFO / OP % | 89.0% | 87.0% | 70.0% | 56.0% | 41.0% |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor days | 65 | 67 | 59 | 114 | 85 |
| Inventory days | 15 | 19 | 42 | 113 | 68 |
| Days payable | 89 | 124 | 107 | 249 | 81 |
| Cash conversion cycle | −10 | −39 | −6 | −24 | 71 |
| Working capital days | 2 | 1 | 15 | 46 | 83 |
| ROCE % | 237.0% | 111.1% | 85.1% | 60.0% | 40.1% |
For the Mar 2026 quarter, Influx Healthtech reported sales of ₹79.76 Cr, up 40.3% year on year and net profit of ₹11.02 Cr, up 37.4% year on year. The operating margin was 18.9%.
Influx Healthtech's sales for the year to Mar 2026 were ₹147 Cr.
Net profit for the year to Mar 2026 was ₹21.04 Cr. Earnings per share over the same trailing period were ₹8.89.
Influx Healthtech reported borrowings of ₹0 Cr at Mar 2026, against cash and equivalents of ₹25.19 Cr.
Cash from operations was ₹4.01 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹20.97 Cr.